RecruitingNCT06837454

French Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD)


Sponsor

Sanofi

Enrollment

600 participants

Start Date

Feb 4, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The objective of the study is to describe the therapeutic management of patients more than or equal to 18 years old eligible for systemic therapy or treated by systemic therapy for atopic dermatitis (AD). This study will be proposed to a sample of French dermatologists experienced in the management of AD, practicing in hospital centers and/or office-based dermatologists. The study will be conducted in real conditions of practice, systemic treatment decisions will be taken at the sole initiative of the participating physician irrespective of the patient enrollment decision. Each patient will be followed-up in routine care setting for 1 year.


Eligibility

Min Age: 18 Years

Inclusion Criteria6

  • Signed informed consent form.
  • Patient with moderate to severe AD according to the Investigator's judgment and
  • Patient eligible to systemic treatment as Atopic Dermatitis Control Tool (ADCT) more than or equal to (≥) 7 and/or use topical corticosteroids (TCS) more than (>) 90 gram (g)/month and/or TCS are not advisable.
  • or
  • Patient currently under systemic treatment.
  • Able to understand and complete study-related questionnaires.

Exclusion Criteria5

  • Any condition that, in the opinion of the Investigator, may interfere with patient's ability to participate in the study, such as short life expectancy, substance abuse, severe cognitive impairment, or other comorbidities that can predictably prevent the patient from adequately completing, as per routine care, the schedule of visits and assessments
  • Patient receiving systemic therapy only for a disease other than AD.
  • Patient participating in any interventional clinical trial at the time of enrolment.
  • Patient is under tutorship or curatorship; patient under safeguard of justice or deprived of his/her liberty by an administrative or court decision
  • The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(60)

Investigational Site Number: 2500051

Aix-en-Provence, France

Investigational Site Number: 2500023

Amiens, France

Investigational Site Number: 2500004

Angers, France

Investigational Site Number: 2500017

Angers, France

Investigational Site Number: 2500050

Arès, France

Investigational Site Number: 2500063

Arès, France

Investigational Site Number: 2500054

Bayonne, France

Investigational Site Number: 2500043

Bezannes, France

Investigational Site Number: 2500040

Biarritz, France

Investigational Site Number: 2500036

Bordeaux, France

Investigational Site Number: 2500053

Bordeaux, France

Investigational Site Number: 2500013

Chalon-sur-Saône, France

Investigational Site Number: 2500026

Chalon-sur-Saône, France

Investigational Site Number: 2500046

Chalon-sur-Saône, France

Investigational Site Number: 2500041

Châlons-en-Champagne, France

Investigational Site Number: 2500018

Cherbourg, France

Investigational Site Number: 2500020

Cholet, France

Investigational Site Number: 2500048

Clermond Ferrand, France

Investigational Site Number: 2500059

Contamine-sur-Arve, France

Investigational Site Number: 2500010

Dunkirk, France

Investigational Site Number: 2500047

Estrées-Deniécourt, France

Investigational Site Number: 2500049

Fort-de-france, France

Investigational Site Number: 2500032

La Ravoire, France

Investigational Site Number: 2500044

La Ravoire, France

Investigational Site Number: 2500011

La Roche-sur-Yon, France

Investigational Site Number: 2500037

La Tronche, France

Investigational Site Number: 2500056

Le Mans, France

Investigational Site Number: 2500068

Le Mans, France

Investigational Site Number: 2500001

Le Mans, France

Investigational Site Number: 2500012

Le Puy-en-Velay, France

Investigational Site Number: 2500003

Limoges, France

Investigational Site Number: 2500031

Loperhet, France

Investigational Site Number: 2500060

Marseille, France

Investigational Site Number: 2500055

Monaco, France

Investigational Site Number: 2500058

Mont-de-Marsan, France

Investigational Site Number: 2500070

Mont-Saint-Aignan, France

Investigational Site Number: 2500033

Niort, France

Investigational Site Number: 2500005

Paris, France

Investigational Site Number: 2500030

Paris, France

Investigational Site Number: 2500009

Paris, France

Investigational Site Number: 2500028

Périgueux, France

Investigational Site Number: 2500027

Périgueux, France

Investigational Site Number: 2500029

Rennes, France

Investigational Site Number: 2500035

Rennes, France

Investigational Site Number: 2500021

Romans-sur-Isère, France

Investigational Site Number: 2500022

Rouen, France

Investigational Site Number: 2500025

Saint-Etienne, France

Investigational Site Number: 2500062

Saint-Gervais-les-Bains, France

Investigational Site Number: 2500076

Saint-Martin, France

Investigational Site Number: 2500034

Saint-Maur-des-Fossés, France

Investigational Site Number: 2500008

Saint-Maur-dès-Faussés, France

Investigational Site Number: 2500045

Saint-Quentin, France

Investigational Site Number: 2500057

Sainte-Eulalie, France

Investigational Site Number: 2500019

Sainte-Maxime, France

Investigational Site Number: 2500015

Toulouse, France

Investigational Site Number: 2500016

Tours, France

Investigational Site Number: 2500038

Vannes, France

Investigational Site Number: 2500024

Villefranche-sur-Saône, France

Investigational Site Number: 2500052

Villeurbanne, France

Investigational Site Number: 2500066

Villeurbanne, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06837454


Related Trials